INTERMACS Registry Will Light The Way To Earlier VAD Therapy – Editorial
This article was originally published in The Gray Sheet
Executive Summary
The ongoing INTERMACS registry holds the key to expanding the usefulness of ventricular assist devices from just extending life to improving the quality of life, according to Lynne Warner Stevenson, cardiac surgeon at Brigham and Women's Hospital, Boston
You may also be interested in...
Warning Letter Cites Thoratec For Inadequate Response To A Patient Death
FDA outlines Thoratec's alleged late reporting and inadequate investigation of a patient death that may have been related to the HeartMate II left ventricular assist device.
NIH Group Proposes Ventricular Assist Study For “Less Sick” Patients
The National Heart Lung and Blood Institute and an interdisciplinary team of experts is trying to develop a multi-device clinical trial to test the benefits of ventricular assist devices in patients with advanced, but not end-stage, heart failure
NIH Group Proposes Ventricular Assist Study For “Less Sick” Patients
The National Heart Lung and Blood Institute and an interdisciplinary team of experts is trying to develop a multi-device clinical trial to test the benefits of ventricular assist devices in patients with advanced, but not end-stage, heart failure